Context Therapeutics Inc. · NASDAQ:CNTX

Context Therapeutics — Investor Presentation (May 2024)

24 slides from Context Therapeutics's investor presentation, May 2, 2024

Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors
May 2024 Corporate Presentation Advancing Medicines for Solid Tumors
Slide 2: Important Notice and Disclaimers
Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and is subject to risks, uncertainties, assumptions and changes in circumstances
Slide 3: Executive Summary: Lead Program CTIM-76, a CLDN6 x CD3 Bispecific Antibody
Lead Program: CTIM-76, a Claudin 6 (CLDN6) x CD3 Bispecific Antibody Executive Summary Context Therapeutics Inc. - May 20243 Lead Asset CTIM-76 is a potentially best-in-class CLDN6 T cell engaging (TCE) bispecific antibody • CLDN6 is enriched in a wide range of cancers, but absent or expressed at lo
Slide 4: TCE Bispecific Data Targeting DLL3, PSMA, and STEAP1
TCE Bispecific Data Targeting DLL3, PSMA, and STEAP1 Recent data supports promising efficacy with low rate of ≥ Grade 3 cytokine release syndrome (CRS) Asset Tarlatamab (AMG757) HPN328 JANX007 Xaluritamig (AMG509) Bispecific Format HLE BiTE (truncated Fc) TriTAC (albumin) TRACTr (albumin) XmAb 2 x 1
Slide 5: CLDN6 Therapies Have the Potential to Reach a Large Patient Population
CLDN6 Therapies Have the Potential to Reach a Large Patient Population >50,000 patients per year in the US only in Relapse/Refractory (R/R) Setting Executive Summary 5 Context Therapeutics Inc. - May 2024 Initial indications of interest based on: • CLDN6 prevalence • Patient population size • Observ
Slide 6: CLDN6 Clinical Proof of Concept in Ovarian and Testicular Cancers
CLDN6 Clinical Proof of Concept in Ovarian and Testicular Cancers Executive Summary Context Therapeutics Inc. - May 20246 BNT211 (CLDN6 CART) TORL-1-23 (CLDN6 ADC) Cutoff Date September 10, 20231 September 29, 20232 Patients (n) 44 (38 evaluable) Ovarian = 17 Testicular = 16 Other =11 42 (36 evaluab
Slide 7: Claudin 6 (CLDN6): Target biology and therapeutic rationale
Claudin 6 (CLDN6) Target biology and therapeutic rationale Context Therapeutics Inc. - May 20247
Slide 8: CLDN6 is an Oncofetal Protein
CLDN6 is an Oncofetal Protein Oncofetal proteins are considered favorable candidates for immunotherapy • Normally present at higher levels during embryonic development • Turned off or have low levels of expression in adult tissues • Increased expression across many solid tumors CLDN6 Target Biology
Slide 9: CLDN6 is Selectively Expressed on Cancer Cells
CLDN6 is Selectively Expressed on Cancer Cells CLDN6 Target Biology Context Therapeutics Inc. - May 20249 (a) adrenal gland, (b) fallopian tube, (c) kidney, (d) liver, (e) thyroid, (f) prostate, (g) esophagus, (h) stomach, (i) colon, (j) cerebrum, (k) cerebellum, (l) spinal cord, (m) thymus, (n) spl
Slide 10: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients
High CLDN6 Associated with a Worsened Prognosis in Cancer Patients CLDN6 Target Biology Context Therapeutics Inc. - May 202410 Endometrial Cancer1 Overexpression of CLDN6 is associated with worse overall survival in endometrial cancer patients 1 Kojima, Cancers, 2020; 2 Zhang, Front. Cell Dev. Biol.
Slide 11: CLDN6 Has Limited Overlap with Competing Targets for Female Reproductive Cancers
CLDN6 Has Limited Overlap with Competing Targets for Female Reproductive Cancers CLDN6 Target Biology Context Therapeutics Inc. - May 202411 Bishop, AnalyzeR [Data Set] Accessed March 1, 2024 Female Reproductive Cancer Correlation between CLDN6 and other targets via RNAseq biopsy data CLDN6 vs. FRαC
Slide 12: CTIM-76: Claudin 6 x CD3 Development Candidate
CTIM-76 Claudin 6 x CD3 Development Candidate Context Therapeutics Inc. - May 202412
Slide 13: Developing a Highly Selective CLDN6 Antibody is Challenging
Developing a Highly Selective CLDN6 Antibody is Challenging CTIM-76 Program Context Therapeutics Inc. - May 202413 CLDN9 CLDN6 CLDN4 CLDN3 CLDN5 CLDN8 CLDN17 CLDN2 CLDN14 CLDN20 CLDN7 CLDN1 CLDN19 CLDN34 CLDN12 CLDN23 CLDN16 CLDN24 CLDN22 CLDN25 CLDN18 CLDN11 CLDN15 CLDN10 • CLDN6 antigen is conform
Slide 14: CTIM-76: Claudin 6 x CD3 T cell Engaging Bispecific Antibody
CTIM-76: Claudin 6 x CD3 T cell Engaging (TCE) Bispecific Antibody Established bispecific format • Highly selective CLDN6 binding fragment antibody-binding (Fab) arm • Immunostimulatory CD3 binding single-chain fragment variable (scFv) domain is functionally monovalent to avoid aberrant T-cell activ
Slide 15: CTIM-76: Selectivity, Potency and In Vivo Efficacy
CTIM-76 Program CTIM-76: T cell engaging (TCE) CLDN6 x CD3 Bispecific Antibody Context Therapeutics Inc. - May 202415 Selectivity Potency In Vivo Efficacy • CTIM-76 CLDN6 EC50 of 3.41 nM (binding) • CTIM-76 preferentially binds to CLDN6 over CLDN3/4/9 • CLDN3/4/6/9 were transiently transfected in HE
Slide 16: CTIM-76 Phase 1a/b Study
CTIM-76 Phase 1a/b Study An open-label, multi-center, dose escalation / expansion, safety, and PK study • Target population ̶ Platinum resistant ovarian cancer ̶ Endometrial and testicular cancer relapsed to standard of care • Biomarker stratification ̶ CLDN6+ positive (10% ≥ 1+) ovarian and endomet
Slide 17: Competitive Landscape
Competitive Landscape 17 Context Therapeutics Inc. - May 2024
Slide 18: CLDN6 Competitive Landscape: Strategy
CLDN6 Competitive Landscape Strategy Assets in Development Assets in the Clinic Characteristics Bispecific 7 3 • Weak internalization makes CLDN6 ideal for bispecific targeting • Selective expression in cancer cells potentially mitigates CRS risk • Potential to address low-to-high CLDN6 expression d
Slide 19: CLDN6 Competitive Landscape
CLDN6 Competitive Landscape Context Therapeutics Inc. - May 202419 Scalable Manufacturing Process Complex Manufacturing Process Potential / Disclosed Safety Liabilities Selectivity for CLDN6 vs CLDN3,4,9 Limited Information on Asset Limited Selectivity Deprioritized CLDN6-CAR-NK CAR-NK + IL7 FPI Q2
Slide 20: CLDN6 x CD3 T Cell Engaging Bispecifics
CLDN6 x CD3 T Cell Engaging Bispecifics Competitive Landscape 20 CTIM-76 XmAb541 AMG794 SAIL66 NBL-028 Beigene Company Context Xencor Amgen Chugai NovaRock Beigene Stage IND Open IND Open Ph 1 (active, not recruiting)1 Ph 1 Ph 1 IND filed Dec 2023 Bispecific Format 1 + 1 2 + 1 HLE Bite Dual Specific
Slide 21: Corporate
Corporate 21 Context Therapeutics Inc. - May 2024
Slide 22: Experienced Leadership Team
Corporate Experienced Leadership Team • Experienced team • Our management team is supported by a Board with strong public company operating and governance experience Focus on Execution Martin Lehr CEO and Director Alex Levit, Esq Chief Legal Officer Jennifer Minai, CPA Chief Financial Officer Chris
Slide 23: Investment Highlights
Corporate Investment Highlights (Nasdaq: CNTX) Solid Tumors Large Unmet Need Claudin 6 High-Value Target IND cleared April 2024 On track for first patient enrolled mid-2024 Milestones Oncology experience Strong Team Expected cash runway into 2028 Cash Runway Context Therapeutics Inc. - May 202423

Context Therapeutics — Investor Presentation (May 2024) on 6ix

Context Therapeutics — Investor Presentation (May 2024)

Slide 1: Corporate Presentation: Advancing Medicines for Solid Tumors

Slide 2: Important Notice and Disclaimers

Slide 3: Executive Summary: Lead Program CTIM-76, a CLDN6 x CD3 Bispecific Antibody

Slide 4: TCE Bispecific Data Targeting DLL3, PSMA, and STEAP1

Slide 5: CLDN6 Therapies Have the Potential to Reach a Large Patient Population

Slide 6: CLDN6 Clinical Proof of Concept in Ovarian and Testicular Cancers

Slide 7: Claudin 6 (CLDN6): Target biology and therapeutic rationale

Slide 8: CLDN6 is an Oncofetal Protein

Slide 9: CLDN6 is Selectively Expressed on Cancer Cells

Slide 10: High CLDN6 Associated with a Worsened Prognosis in Cancer Patients

Slide 11: CLDN6 Has Limited Overlap with Competing Targets for Female Reproductive Cancers

Slide 12: CTIM-76: Claudin 6 x CD3 Development Candidate

Slide 13: Developing a Highly Selective CLDN6 Antibody is Challenging

Slide 14: CTIM-76: Claudin 6 x CD3 T cell Engaging Bispecific Antibody

Slide 15: CTIM-76: Selectivity, Potency and In Vivo Efficacy

Slide 16: CTIM-76 Phase 1a/b Study

Slide 17: Competitive Landscape

Slide 18: CLDN6 Competitive Landscape: Strategy

Slide 19: CLDN6 Competitive Landscape

Slide 20: CLDN6 x CD3 T Cell Engaging Bispecifics

Slide 21: Corporate

Slide 22: Experienced Leadership Team

Slide 23: Investment Highlights

Slide 24: Advancing Medicines for Solid Tumors